Sensient Technologies (SXT)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
Research Workspace
Put SXT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 10% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 45%, softest on free-cash-flow margins.
View QualityManagement screens strong on earnings delivery, margins.
View ManagementExpectations look high — the market is pricing in about 34% growth a year, above the roughly 13% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskSensient's natural color growth has to keep compounding to justify the price. Revenue grew 10.6% in the latest quarter. The company beat earnings expectations by 9.7%. It trades at 29x earnings versus a 17x peer median. The market is pricing in more growth than we forecast. Management is running behind on a stated commitment. Peer multiples imply a price about 46% below where it trades. Our read is on watch. This read is provisional.
Trailing returns as of 2026-11-04. SXT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering SXT (as of Nov 2026).
Based on 3 Wall Street analysts offering 12-month price targets for SXT in the last 4 months.
Continue this research
Compare SXT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SXT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put SXT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand Color segment revenue and operating income
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $125.82
The last 12 months of price, then the range of analyst 12-month targets from today’s $125.82.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Q3 EPS beat and accelerating natural-color growth support Color segment expansion, though no magnitude or outlook details are provided.

Advances: Expand Color segment revenue and operating income
Capex supports natural-color capacity and the stated 2028 conversion target, advancing Color growth.

Earnings beat and raised guidance support revenue and EPS growth objectives.
